American Oriental Bioengineering, Inc. (AOBI)
OTCMKTS · Delayed Price · Currency is USD
0.0012
+0.0001 (9.09%)
At close: Oct 20, 2025
AOBI Revenue
American Oriental Bioengineering had revenue of $17.94M in the quarter ending September 30, 2013, a decrease of -34.65%. This brings the company's revenue in the last twelve months to $121.58M, down -10.20% year-over-year. In the year 2012, American Oriental Bioengineering had annual revenue of $145.10M, down -31.78%.
Revenue (ttm)
121.58M
Revenue Growth
-10.20%
P/S Ratio
n/a
Revenue / Employee
32.69K
Employees
3,719
Market Cap
88.00
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2012 | 145.10M | -67.59M | -31.78% |
| Dec 31, 2011 | 212.69M | -93.25M | -30.48% |
| Dec 31, 2010 | 305.94M | 9.79M | 3.31% |
| Dec 31, 2009 | 296.15M | 31.51M | 11.91% |
| Dec 31, 2008 | 264.64M | 104.16M | 64.90% |
| Dec 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2005 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2004 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2003 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Zomedica | 29.45M |
| Silence Therapeutics | 25.83M |
| Northwest Biotherapeutics | 937.00K |